Liu Jian, Wang Lei, Wang Tongqing, Wang Jizheng
Department of Urology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
Oncol Lett. 2018 Oct;16(4):4325-4330. doi: 10.3892/ol.2018.9145. Epub 2018 Jul 13.
Expression of interleukin-23 receptor (IL-23R) and IL-17 in urinary bladder carcinoma (UBC) was investigated to explore the correlations with prognosis. IL-23/IL-17 axis significantly inhibited the development of inflammatory bowel disease. Thirty patients with UBC were enrolled in Zhengzhou Central Hospital Affiliated to Zhengzhou University from September 2013 to September 2014. Tumor tissue and adjacent healthy tissue were collected, and the levels of IL-23R and IL-17 mRNA were detected by RT-PCR. Thirty healthy people were also selected to serve as normal control group. Serum levels of IL-23R and IL-17 in serum of UBC patients and normal controls were detected by ELISA, and the correlations with clinical features of UBC were analyzed. Pearson's correlation analysis was used to analyze the correlation between IL-23R and IL-17 protein expression. Follow-up study was performed by phone or during patient's visit to out-patient department. Overall survival (OS) and disease-free survival (DFS) curves were plotted by Kaplan-Meier method to analyze the correlation between expression of IL-23R and IL-17 and survival time. ROC curve was used to detect the diagnostic values of IL-23R and IL-17 protein for UBC. Levels of IL-23R and IL-17 mRNA in UBC tissue were 3.26 and 2.65 times higher than those in adjacent tissue (P<0.05), and serum levels of IL-23R and IL-17 protein in UBC patients were significantly higher than those in normal control group. Protein expression levels of IL-23R and IL-17 were correlated with clinical stage and lymph node metastasis in UBC patients (P<0.05), and Cox hazard model showed that L-23R and IL-17 expression may be independent factors for UBC (P<0.05), and high expression levels of IL-23R and IL-17 significantly shortened the OS and DFS (P<0.05). Serum levels of IL-23R and IL-17 can be used to effectively diagnose clinical stage and lymph node metastasis of UBC patients, and the combined diagnosis has a higher sensitivity and specificity than the diagnosis using a single factor. These findings indicated that expression levels of IL-23R and IL-17 were increased in tumor tissue and serum of UBC patients, and the increased expression levels of IL-23R and IL-17 were correlated with poor prognosis. Detection of IL-23R and IL-17 levels has certain clinical significance in the diagnosis and prognosis of UBC.
研究了白细胞介素-23受体（IL-23R）和IL-17在膀胱癌（UBC）中的表达，以探讨其与预后的相关性。IL-23/IL-17轴显著抑制炎症性肠病的发展。2013年9月至2014年9月，郑州大学附属郑州中心医院纳入了30例UBC患者。收集肿瘤组织和相邻的健康组织，通过逆转录聚合酶链反应（RT-PCR）检测IL-23R和IL-17 mRNA的水平。还选取了30名健康人作为正常对照组。采用酶联免疫吸附测定（ELISA）检测UBC患者血清和正常对照血清中IL-23R和IL-17的水平，并分析其与UBC临床特征的相关性。采用Pearson相关分析来分析IL-23R和IL-17蛋白表达之间的相关性。通过电话或患者门诊就诊时进行随访研究。采用Kaplan-Meier法绘制总生存（OS）和无病生存（DFS）曲线，以分析IL-23R和IL-17表达与生存时间的相关性。采用ROC曲线检测IL-23R和IL-17蛋白对UBC的诊断价值。UBC组织中IL-23R和IL-17 mRNA的水平分别比相邻组织高3.26倍和2.65倍（P<0.05），UBC患者血清中IL-23R和IL-17蛋白的水平显著高于正常对照组。UBC患者中IL-23R和IL-17的蛋白表达水平与临床分期和淋巴结转移相关（P<0.05），Cox风险模型显示IL-23R和IL-17表达可能是UBC的独立因素（P<0.05），IL-23R和IL-17的高表达水平显著缩短了OS和DFS（P<0.05）。血清中IL-23R和IL-17的水平可用于有效诊断UBC患者的临床分期和淋巴结转移，联合诊断比单因素诊断具有更高的敏感性和特异性。这些发现表明，UBC患者肿瘤组织和血清中IL-23R和IL-17的表达水平升高，且IL-23R和IL-17表达水平升高与预后不良相关。检测IL-23R和IL-17水平在UBC的诊断和预后中具有一定的临床意义。
